Share

Webcasts of 3rd EORTC QOL, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference

View webcasts of the 3rd EORTC QOL, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference held at the European Parliament on17-19 October 2012.

3rd EORTC Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference received funding from the European Union in the framework of the Health Programme.

Four investigators received awards during the 3rd Quality of Life Conference closing ceremony

Dr. Andrew Bottomley, conference chair and EORTC Assistant Director, congratulates Joseph O’Connell, Best Oral Presentation by Advanced Career Investigator, and Karoline Albrecht, Best Oral Presentation by Early Career Investigator.

The Best Oral Presentation by an Early Career Investigator was awarded to Ms. Karoline Albrecht from the University of Freiburg Medical Center in Germany for her talk on “HRQOL and side-effects in the course of low-dose interferon therapy in comparison to a control group without interferon”. The Best Oral Presentation by an Advanced Career Investigator was awarded to Dr. Joseph O’Connell from Oncology Research and Development at Pfizer, New York, United States of America, for his talk on “Symptom impact of dacomitinib in patients with advanced lung cancer after chemotherapy failure: results from a phase II randomized trial”. The Best Poster Presentation by Early Career Investigator was awarded to Dr. Emily Symington from the Addenbrookes Cambridge University Hospital in the United Kingdom, and the Best Poster Presentation by an Advanced Career Investigator was awarded to Dr. Amelie Harle from the Christie Hospital in the United Kingdom.

Press releases from the 3rd EORTC Quality of Life, Symptom Research and Patient Reported Outcomes in Cancer Clinical Trials Conference

18 October 2012

19 October 2012

 

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023